Martin Cara M, Kehoe Louise, Spillane Cathy O, O'Leary John J
Department of Pathology, Coombe Women's Hospital, Dublin, Ireland.
Mol Diagn Ther. 2007;11(5):277-90. doi: 10.1007/BF03256249.
Cervical cancer is a potentially preventable disease; however, it remains the second most common malignancy in women worldwide. The human papillomavirus (HPV) is the single most important etiological agent in cervical cancer. HPV contributes to neoplastic progression through the action of two viral oncoproteins E6 and E7, which interfere with critical cell cycle pathways, tumor protein p53, and retinoblastoma protein. However, evidence suggests that HPV infection alone is insufficient to induce malignant changes, and other host genetic variations are important in the development of cervical cancer. Advances in molecular biology and high throughput technologies have heralded a new era in biomarker discovery and identification of molecular targets related to carcinogenesis. These advancements have improved our understanding of carcinogenesis and will facilitate screening, early detection, management, and personalized targeted therapy. A number of these developments and molecular targets associated with cervical cancer will be addressed in this review.
宫颈癌是一种潜在可预防的疾病;然而,它仍是全球女性中第二常见的恶性肿瘤。人乳头瘤病毒(HPV)是宫颈癌唯一最重要的病因。HPV通过两种病毒癌蛋白E6和E7的作用促进肿瘤进展,这两种蛋白会干扰关键的细胞周期途径、肿瘤蛋白p53和视网膜母细胞瘤蛋白。然而,有证据表明,仅HPV感染不足以诱发恶性变化,其他宿主基因变异在宫颈癌的发生发展中也很重要。分子生物学和高通量技术的进步开创了生物标志物发现以及与致癌作用相关分子靶点鉴定的新时代。这些进展增进了我们对致癌作用的理解,并将促进筛查、早期检测、管理和个性化靶向治疗。本综述将探讨其中一些与宫颈癌相关的进展和分子靶点。